Inhaled nitric oxide in congenital heart disease.
- 1 February 1993
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 87 (2), 447-453
- https://doi.org/10.1161/01.cir.87.2.447
Abstract
BACKGROUND Congenital heart lesions may be complicated by pulmonary arterial smooth muscle hyperplasia, hypertrophy, and hypertension. We assessed whether inhaling low levels of nitric oxide (NO), an endothelium-derived relaxing factor, would produce selective pulmonary vasodilation in pediatric patients with congenital heart disease and pulmonary hypertension. We also compared the pulmonary vasodilator potencies of inhaled NO and oxygen in these patients. METHODS AND RESULTS In 10 sequentially presenting, spontaneously breathing patients, we determined whether inhaling 20-80 ppm by volume of NO at inspired oxygen concentrations (FIO2) of 0.21-0.3 and 0.9 would reduce the pulmonary vascular resistance index (Rp). We then compared breathing oxygen with inhaling NO. Inhaling 80 ppm NO at FIO2 0.21-0.3 reduced mean pulmonary artery pressure from 48 +/- 19 to 40 +/- 14 mm Hg and Rp from 658 +/- 421 to 491 +/- 417 dyne.sec.cm-5.m-2 (mean +/- SD, both p < 0.05). Increasing the FIO2 to 0.9 without adding NO did not reduce mean pulmonary artery pressure but reduced Rp and increased the ratio of pulmonary to systemic blood flow (Qp/Qs), primarily by increasing Qp (p < 0.05). Breathing 80 ppm NO at FIO2 0.9 reduced mean pulmonary artery pressure and Rp to the lowest levels and increased Qp and Qp/Qs (all p < 0.05). While breathing at FIO2 0.9, inhalation of 40 ppm NO reduced Rp (p < 0.05); the maximum reduction of Rp occurred while breathing 80 ppm NO. Inhaling 80 ppm NO at FIO2 0.21-0.9 did not alter mean aortic pressure or systemic vascular resistance. Methemoglobin levels were unchanged by breathing up to 80 ppm NO for 30 minutes. CONCLUSIONS Inhaled NO is a potent and selective pulmonary vasodilator in pediatric patients with congenital heart disease complicated by pulmonary artery hypertension. Inhaling low levels of NO may provide an important and safe means for evaluating the pulmonary vasodilatory capacity of patients with congenital heart disease without producing systemic vasodilation.Keywords
This publication has 24 references indexed in Scilit:
- Inhaled Nitric Oxide for the Adult Respiratory Distress SyndromeNew England Journal of Medicine, 1993
- Inhaled Nitric Oxide A Selective Pulmonary Vasodilator of Heparin-Protamine Vasoconstriction in SheepAnesthesiology, 1991
- Comparison of Effects of Prostaglandin E1 and Nitroprusside on Pulmonary Vascular Resistance in Children After Open-Heart SurgeryThe Annals of Thoracic Surgery, 1981
- The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholineNature, 1980
- Effects of nitroprusside and dopamine on pulmonary arterial vasculature in children after cardiac surgery.Circulation, 1979
- Pulmonary vascular disease in complete atrioventricular canal defectThe American Journal of Cardiology, 1977
- Development of the pulmonary circulation in ventricular septal defect: A quantitative structural studyThe American Journal of Cardiology, 1977
- The pulmonary vascular bed in children with Down syndromeThe Journal of Pediatrics, 1975
- Oxygen consumption in infants with heart disease: Relationship to severity of congestive failure, relative weight, and caloric intakeThe Journal of Pediatrics, 1972
- Effects of tolazoline hydrochloride (priscoline) on circulatory dynamics of patients with pulmonary hypertensionAmerican Heart Journal, 1958